On July 20, 2020, DAC Biotech’s new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue.Read more
Blog
By medicilon | Medicilon Events | Comments are Closed | 20 July, 2020 |